NCT03506451

Brief Summary

The purpose of this single institution, pilot study is to explore the out of pocket (OOP)costs and financial toxicity of cancer care for patients during definitive treatment of head and neck cancer with radiation therapy with or without chemotherapy and surgical resection. The study team will assess how the financial burden of cancer care impacts quality of life as well as treatment-related decision-making from a patient perspective.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable head-and-neck-cancer

Timeline
Completed

Started Jun 2018

Longer than P75 for not_applicable head-and-neck-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 20, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 24, 2018

Completed
2 months until next milestone

Study Start

First participant enrolled

June 19, 2018

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 29, 2021

Completed
4.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 13, 2026

Completed
Last Updated

May 6, 2026

Status Verified

May 1, 2026

Enrollment Period

3.4 years

First QC Date

April 20, 2018

Last Update Submit

May 4, 2026

Conditions

Keywords

Financial toxicity

Outcome Measures

Primary Outcomes (3)

  • Financial toxicity, as measured by out of pocket (OOP) costs for a definitive course of treatment for HNC

    3 months post radiation therapy

  • Financial toxicity, as measured by out of pocket (OOP) costs for a definitive course of treatment for HNC

    6 months post radiation therapy

  • Financial toxicity, as measured by change in Comprehensive Score for financial Toxicity (COST)

    Financial toxicity will be measured using the comprehensive score for financial toxicity (COST). The range of the COST score is 0-44.

    Baseline, 3 months post radiation therapy, 6 months post radiation therapy

Secondary Outcomes (3)

  • Change in symptom burden, as measured by Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) score

    Baseline, 3 months post radiation therapy, 6 months post radiation therapy

  • Change in quality of life, as measured by FACT-H&N score

    Baseline, 3 months post radiation therapy, 6 months post radiation therapy

  • Perceived quality of care

    3 months post radiation therapy, 6 months post radiation therapy

Other Outcomes (3)

  • Disease status

    5 years post completion of radiation treatment

  • Overall survival

    5 years post completion of radiation treatment

  • Progression free survival

    5 years post completion of radiation treatment

Study Arms (1)

Single arm non-therapeutic interventional study

OTHER

All subjects who enroll on study will be asked to complete questionnaires at baseline before treatment starts; the questionnaires are repeated at one month, three and six months after radiation therapy has been completed. the demographics questionnaire is completed at baseline only; the FACT-HN is completed at all four time points.

Other: Demographics questionnaires and the FACT HN questionnaire

Interventions

Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.

Single arm non-therapeutic interventional study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (18 years or older) patients
  • Diagnosed with HNC with treatment plan including definitive radiation therapy or chemotherapy/radiation therapy
  • Be able to read and write in English
  • Able to give informed consent and complete survey materials

You may not qualify if:

  • Recurrent disease
  • Metastatic disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke Cancer Center

Durham, North Carolina, 27710, United States

Location

MeSH Terms

Conditions

Head and Neck NeoplasmsFinancial Stress

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsStress, PsychologicalBehavioral SymptomsBehavior

Study Officials

  • Pooja Karukonda, MD

    Duke University Health System (DUHS)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 20, 2018

First Posted

April 24, 2018

Study Start

June 19, 2018

Primary Completion

November 29, 2021

Study Completion

April 13, 2026

Last Updated

May 6, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations